Journal article
Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013
Abstract
Despite nine studies reporting the results achieved when treating patients with chronic myeloid leukemia (CML) with interferon (rIFNalpha) and cytarabine (araC), the optimal doses and schedule for this combination remain to be determined. Results of imatinib mesylate (STI-571) in chronic phase CML are preliminary, thus, trials of rIFNalpha-2b/araC in CML are of continued interest. We report the results of CALGB study 9013, providing a 10-year …
Authors
Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
Journal
Leukemia & Lymphoma, Vol. 44, No. 1, pp. 39–48
Publisher
Taylor & Francis
Publication Date
January 2003
DOI
10.1080/1042819021000040260
ISSN
1042-8194
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlotting, SouthernCentral Nervous System DiseasesCytarabineDrug Administration ScheduleFemaleFollow-Up StudiesFusion Proteins, bcr-ablHumansInterferon alpha-2Interferon-alphaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedRecombinant ProteinsSurvival AnalysisCohort StudiesCost-Benefit AnalysisFinancing, OrganizedHealth ExpendituresHematopoietic Stem Cell TransplantationMelphalanModels, StatisticalMultiple MyelomaPrednisone